What is Thor Medical ASA's (TRMED.OL) StockRank?

MoatMap's StockRank for Thor Medical ASA (TRMED.OL) is 20/100, with a Sell signal. This is a composite score combining Quality (29), Value (25), and Momentum (52) factor ranks across MoatMap's 20,000+ stock universe.

Does Thor Medical ASA have an economic moat?

Thor Medical ASA (TRMED.OL) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Thor Medical ASA a buy, hold, or sell?

MoatMap's current signal for Thor Medical ASA (TRMED.OL) is Sell, based on a StockRank of 20/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Thor Medical ASA in?

Thor Medical ASA (TRMED.OL) operates in the Healthcare sector, specifically the Biotechnology industry (Norway).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

TRMED.OL

SELLREMOVE

Thor Medical ASA · Healthcare · Norway · $157M · Avg Vol: $548K/d

StockRank

P/E (TTM)

—

ROE

-14.6%

D/E

0.4x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Early-stage Norwegian biotech with highly speculative cash flows and no established commercial moat, failing our quality compounder criteria.

COMPANY DESCRIPTION

Thor Medical ASA is a biotechnology company developing alpha-particle emitters, specifically alpha-emitting radionuclides like bismuth-212 and lead-212, for targeted cancer therapies. The company utilizes proprietary technology to extract thorium and uranium from industrial waste, positioning itself as a low-cost supplier in the emerging radiopharmaceutical market. Its competitive advantage lies in its unique, environmentally friendly extraction process and strategic raw material access.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	0	0	0	41,284	—
EPS	—	-0.09	-0.02	-0.02	-0.02	—
Shares	—	360.0M	239.7M	281.2M	354.1M	-1.6%
Debt	—	16,410	0	76,066	17.7M	925.3%
Equity	—	6.6M	28.1M	34.8M	47.1M	92.6%
Op CF	—	-42.2M	-6.6M	-2.4M	-4.9M	—
Inv CF	—	-0.3M	0.6M	0.1M	-6.9M	—
Fin CF	—	23.5M	-34,266	10.7M	17.7M	—

PRICE (1Y)-4.3%

SMA 50SMA 200

$0.44

RSI (14)

43.7

52W High

$0.59

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

-9.3%35.0

ROE

-14.6%32.5

GP/Assets

0.1%10.7

Op. Margin

-4932.7%3.5

FCF/Assets

-12.8%24.8

Piotroski

321.6

Int. Cover

-50.0x6.0

D/E Ratio

0.38x38.3

Current Ratio

4.57x67.9

Value

P/E (TTM)

—N/A

EV/EBITDA

-29.4x25.0

P/FCF

—N/A

P/B

3.3x39.4

P/S

1821.5x2.2

Div Yield

—N/A

Momentum

52W High %

74%58.7

RS 6M

-20%49.9

SMA 50/200

1.05x74.7

EPS Rev 4W

+0.2%67.0

EPS Rev 12W

—N/A

EPS Improve

—45.9

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$157M

P/E (Forward)

-38.6x

Gross Margin

100.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TRMED.OL are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
TRMED.OL	Thor Medical ASA(you)	$157M	20	SELL
CRNA.OL	Circio Holding ASA	$232M	20	SELL
ZLNA.OL	Zelluna ASA	$51M	20	SELL
AZT.OL	ArcticZymes Technologies ASA	$107M	45	HOLD
NYKD.OL	Nykode Therapeutics AS	$109M	46	HOLD
PHO.OL	Photocure ASA	$166M	70	BUY
MEDI.OL	Medistim ASA	$438M	86	STRONG BUY
VISTN.OL	Vistin Pharma ASA	$93M	99	STRONG BUY

Peer medians: ROE 16.1% · P/E 23.0x · Gross margin 93.6%

Thor Medical ASA (TRMED.OL) — Stock Score Summary

Thor Medical ASA (TRMED.OL) has a MoatMap StockRank of 20/100 based on Quality (29/100), Value (25/100), and Momentum (52/100) factor scores. The current signal is SELL. Early-stage Norwegian biotech with highly speculative cash flows and no established commercial moat, failing our quality compounder criteria.

Key Financial Metrics

Price	$0.44
Market Cap	$157M
P/E (Forward)	-38.59
Price/Book	3.30
Return on Equity	-14.6%
Return on Invested Capital	-9.3%
Debt/Equity	37.58
Gross Margin	100.0%
Operating Margin	-4932.7%
Free Cash Flow	$-1M

Thor Medical ASA operates in the Biotechnology industry, part of the Healthcare sector (Norway).

Frequently Asked Questions

What is Thor Medical ASA’s (TRMED.OL) StockRank?: MoatMap’s StockRank for Thor Medical ASA (TRMED.OL) is 20/100, with a Sell signal. It is a composite of Quality (29), Value (25), and Momentum (52) factor ranks across MoatMap’s 20,000+ stock universe.
Does Thor Medical ASA have an economic moat?: Thor Medical ASA (TRMED.OL) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Thor Medical ASA a buy, hold, or sell?: MoatMap’s current signal for Thor Medical ASA (TRMED.OL) is Sell, based on a StockRank of 20/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Thor Medical ASA in?: Thor Medical ASA (TRMED.OL) operates in the Healthcare sector, specifically the Biotechnology industry (Norway).